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1. Introduction 
Oocytes designed for reproductive function in women are the largest cell in the human 
body. They are surrounded by granulosa cells to form the follicles that in various stages of 
development are present in the ovarian cortex (Fig. 1).  
 
 
Fig. 1. Primary follicle in frozen/thawed human ovarian cortex (20X magnification) 
The ovary of a healthy woman contains a finite number of follicles that decreases over time. 
The peak number is reached in the fifth month of gestation with approximately 7 million 
follicles. This number reduces progressively due to atresia, so at birth there are only 1-2 
www.intechopen.com
 
Topics in Cancer Survivorship 
 
214 
million follicles that, at puberty, become 300.000. Approximately, 400 of these follicles 
become mature oocytes and ovulate during the fertile life of the female.  
At the age of 37, there is usually an acceleration of follicular loss, which is correlated with an 
increase in follicle-stimulating hormone (FSH) level.  
Last year Wallace reported with a mathematical model combined with histological evidence, 
the establishment and decline of non-growing follicles (NGFs) in the human ovary.  Wallace 
shows for the first time that the rate of NGF  recruitment increases from birth to age 14 years 
and then declines with age until menopause (Fig. 2) (Wallace & Kelsey, 2010).  
 
 
Fig. 2. The best histological model for the establishment of the NGF population after 
conception and the subsequent decline until menopause (Kindly provided by Professor 
Wallace).  
However, the central dogma of ovarian biology has been questioned by new discoveries. 
Johnson in 2004 reported that germline stem cells (GSCs) are present in the mouse ovary, 
and could become new follicles (Johnson et al., 2004). It seems that female germline stem cell 
reside in an extragonadal location, the bone marrow, and reach the ovary through the 
circulatory system (Johnson et al., 2005; Lee et al., 2007). De Felici reported that germline 
stem cells exist in adult mouse ovaries but are quiescent under physiological conditions, 
contributing to the oocyte reserve only in response to ovotoxic damage (De Felici, 2010). 
Recently, Bukovsky showed  the production of new eggs in cultures derived from 
premenopausal and postmenopausal human ovaries (Bukovsky et al., 2009).  
Despite these exciting new prospects to indicate that oocytes are continuously formed in the 
female adult, at the present it is known that the pool of follicles is limited, so in case of toxic 
ovarian events that may affect the ovary, opportune measures should be considered to 
preserve the fertility of young women. According to the law in different countries regulating 
assisted reproductive technologies, approaches to fertility preservation include embryo, 
oocyte cryopreservation, or ovarian tissue banking followed by ovarian tissue transplant or 
in in-vitro culture. 
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However, cryopreservation of ovarian tissue may be the only acceptable method to preserve 
fertility for prepubertal girls, for women who cannot delay the start of cancer treatment for 
ovarian stimulation, and probably for women with hormone-sensitive malignancies. All 
these situations make ovarian tissue freezing the only option for female fertility 
preservation.  
Therefore, an entire ovary or part of it, is removed laparoscopically, frozen and stored in 
liquid nitrogen at -196°C.  After complete recovery of the patient, the tissue can be used to 
restore gametogenic and/or steroidogenic function.  
Potential indications for ovarian tissue cryopreservation are patients diagnosed with 
malignant (extra-pelvic diseases: bone cancer, thyroid cancer, kidney cancer, breast cancer, 
melanoma, neuroblastoma; pelvic diseases: non-gynecological malignancy, gynaecological 
malignancy; systemic diseases: Hodkin’s disease, non-Hodgkin’s lymphoma, leukaemia, 
melanoblastoma) or benign diseases (recurrent ovarian cysts, etc), or with non malignant 
autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, autoimmune 
thrombocytopenia or other haematological diseases).  These patients are being treated 
successfully with chemotherapy and/or radiotherapy or repeated surgery, greatly improved 
in recent years, but all these therapies can be toxic to the ovary.   So, it is important to focus 
attention on the quality of life, including fertility preservation, as well as on survival of these 
young women. 
2. Effect of radiotherapy, chemotherapy, or other toxic drugs on female 
reproduction 
The risk of ovarian failure after anticancer treatments is assessed in relation to patient’s age, 
treatment protocol and type of cancer as reported by Meirow  (Meirow and Nugent, 2001).  
High-dose ionizing radiation is used to treat many types of cancer and hematologic 
malignancies. Ovarian transposition is not possible in case of total irradiation as is required 
for bone marrow transplantation (Meirow et al., 2010). The estimated dose at which half of 
the follicles are lost in humans (LD50) is 4 Gy (Wallace et al., 1989), but is age-dependent. 
Lashbaugh reported that the toxic ovarian dose, which leads to permanent loss of fertility is 
higher in young women (20 Gy) than older (6 Gy) (Lushbaugh & Casarett, 1976).  
Chemoterapic agents can be grouped into five classes of drugs based on their mode of action 
(alkylating agents, aneuploidy inducers, topoisomerase II inhibitors, antimetabolites and 
radiomimetics) as summarized by Meirow. It was found that alkylating agents imposed the 
highest risk in causing ovarian failure with an odd ratio (OR) of 3,98, followed by cisplatin 
with an OR of 1.77 (Meirow and Nugent, 2001).  
Schmidt, reported that the ovaries of healthy young girls contain a higher number of 
follicles than ovaries from older women, meaning young girls are more resistant to 
chemotherapy.  Even if chemotherapeutic agents differ in their ovarian toxicity (Schmidt et 
al., 2010), they are often used in combination, so their adverse effects are increased and 
cannot always be easily evaluated.  
In 2007, Oktem and Oktay, published an interesting paper on ovarian damage from 
chemotherapy. They present the first quantitative evidence in humans, by histological 
evaluation, that alkylating agents can significantly reduce ovarian reserve, and may affect 
stromal cell function (Oktem & Oktay, 2007). Meirow also reported that injury from 
chemotherapy is in stromal cells as well as in follicles and blood vessels (Meirow, 2010). 
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3. Ovarian tissue cryopreservation 
To preserve ovarian tissue for a lengthy period of time, it should be stored in liquid nitrogen 
at a temperature of -196°C. However, ovarian tissue cryopreservation is complex and 
requires preservation of multiple cell types, thus the ability to successfully cryopreserve 
would be a powerful clinical tool in an assisted reproductive laboratory.  
As reported by Bakhach in 2009, is easy to imagine the cell damage when temperatures fall 
from +37°C to -196°C. There is a loss of about 95% of intracellular water, an increase of 
electrolyte concentrations in both intra and extracellular media, and ice formation in the 
intracellular spaces that deform cells and destroy intracellular structures (Bakhach, 2009).  
Hovatta in 2005 published an interesting work on the different methods of ovarian tissue 
freezing which emphasizes the importance of trying to preserve most of the cellular tissue 
components, including even the small proportion of ovarian medulla which contain blood 
vessels and nerves so important for ovarian tissue function recovery after reimplantation 
(Hovatta, 2005). Recently, Donnez reported that revascularization of grafts depends also on 
the preservation of vessels  in grafted tissue, and not only on neoangiogenesis from the host 
(Donnez et al., 2011-b).   
It should be stressed that the protocol of ovarian tissue freezing is still not standardized. So, 
there are several freezing procedures that range from slow freezing/rapid thawing, 
vitrification or ultrarapid-freezing. Freezing protocols differ also depending on the 
cryoprotectants used, dehydration/rehydration time and temperature, different protein 
support, and on the containers used for storage such us cryovials, strips or other tubes.  
Approaches to human ovarian tissue cryopreservation are currently characterised by the use 
of slow freezing/rapid thawing methods using dimethylsulphoxide (DMSO) or propanediol 
(PROH) as a cryoprotectant. The slow freezing requires the use of a machine that slowly 
decreases the temperature, so the freezing programme so takes a few hours. This procedure 
has the disadvantage that it can lead to the formation of ice crystals, affecting correct tissue 
preservation. This disadvantage is avoided by using the protocol of vitrification, where high 
concentrations of cryopotectants are used, which increased ovarian toxicity too. Ultra-rapid 
freezing should be a method somewhere between the previous two using the advantages 
given by vitrification with a lower concentration of cryoprotectant to act on increasing the 
cooling rate.  
In 2003 Shaw published an interesting paper on the terminology associated with 
equilibrium cooling procedures or ‘slow cooling’ and non-equilibrium protocols such as 
‘vitrification’, ‘rapid cooling’ and ‘ultrarapid cooling’ that is helpful in clarifying the terms 
often used inappropriately (Shaw & Jones, 2003).  
The positive results achieved by oocyte vitrification, has been discussed in recent years, but 
at the present time this procedure applied to ovarian tissue has given conflicting results.  
Isachenko has worked extensively on the ovarian tissue vitrification. Her paper of 2007 
showed a better preservation of ovarian tissue by slow freezing in which the quality of 
follicles was higher compared to the rapid freezing (Isachenko et al., 2007; Isachenko et al., 
2009).  
In 2007 Li  demonstrated that the vitrification method for cryopreservation of human 
ovarian tissue is effective and simple (Li et al., 2007). Kagawa in 2009 found no difference in 
oocyte viability between fresh and vitrified human ovarian cortical tissue (kagawa, 2009). In 
another paper ovarian stroma was shown to be significantly better preserved by vitrification 
compared to slow freezing (Keros et al., 2009). 
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However, data on cryopreservation of human ovarian tissues by vitrification are still modest 
and controversial. This may be due to the fact that the same cryopreservation procedure is 
often used, such as slow freezing or vitrification, but different freezing protocol (types of 
cryoprotectant, concentration used and time of diffusion, etc.), this creates significant bias 
that must be considered.  
In addition vitrification presupposes direct contact with liquid nitrogen, which is a potential 
source of microbial contamination, as reported by Isachenko (Isachenko et al., 2009). 
In conclusion, an ideal ovarian cryopreservation method has not yet been established. 
4. How to use 
After 4 or 5 years when the patient is considered oncologically cured, the ovarian tissue 
stored in liquid nitrogen can be used. There are several ways to use tissue after thawing, 
such us reimplantation in various anatomic sites in the same patient or in a host animal or in 
vitro culture to grow primordial follicles present in large number (Fig. 3). 
 
 
Fig. 3. Techniques using human cryopreserved ovarian tissue. 
4.1 Ovarian tissue culture 
When dealing with tumours that can metastasize to the ovary, ovarian tissue reimplantation 
should be avoided due  to the risk of retransmitting cancer cells. In these cases the only 
option is to develop other methods in which the primordial follicles are matured in vitro 
within ovarian tissue pieces. Only in mice was the full maturation of primordial follicles 
with livebirths achieved (Eppig et al., 1996), this is difficult to replicate in large animals and 
humans.  
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In 2008 Picton published an interesting review on in vitro growth and maturation of 
follicles, which showed a number of different culture systems. It showed that culture of thin 
cortical strips has many advantages such as avoiding the damage caused by mechanical or 
enzymatic recovery of follicle present in the cortex, and provides a complex support system 
that resembles the ovary in vivo as the follicles also remain in contact with the surrounding 
stromal cells. This contact is very important at least until development of secondary follicles, 
when the follicles from the surrounding stroma should be left to facilitate further 
development. Thus, a multi-step strategy for the complete in vitro growth and maturation of 
follicles is promoted (Picton et al., 2008). 
Recently another interesting review was published by Fabbri which summarizes the most 
relevant literature of the last ten years on in vitro cultures of ovarian cortical pieces. The 
conclusion was that the current optimal method for growing and maturing human follicles 
remains whole tissue culture. The authors underline the difficult of graduating nutrient 
concentration and especially what is best to add to the culture media and when (Fabbri et 
al., 2009). 
In conclusion the culture of ovarian cortex strips is under development and currently not 
applicable to the human species, owing to the long period necessary for the follicle to 
complete development, almost six months compared to the couple of weeks in mice.  
However, as suggested by Picton before these strategies can be utilised therapeutically, 
extensive testing is required to confirm the epigenetic health and genetic normality of in 
vitro growth derived oocytes (Picton et al., 2008). 
We must not forget that oocytes are matured in vitro, after full development of follicles in 
vitro for a period exceeding 90 days, with the addition of nutrients that are not exactly what 
you get in their natural anatomic site, both as concentration and as timing of administration. 
So, even if complete follicle development in vitro is far from being clinically applicable, this 
does not mean that patients with malignancies that metastasize to the ovary should be 
excluded from the eventuality of cryopreserved tissue. We cannot know whether the study 
of in vitro cultures will make progress in a few years time. 
4.2 Ovarian tissue reimplantation 
The main option of this strategy is to transplant cortical ovarian tissue into the pelvic cavity, 
into its original location (orthotopic site) or in a different site, such as forearm, arm, 
abdominal wall, etc. (heterotopic site) when anticancer treatment is completed and the 
patient is disease-free.  
Human transplantation history begins in the heterotopic site, such as the arm or the 
forearm. First studies on heterotopic reimplantation of an organ date back to 1975 and were 
applied to parathyroid gland. Several authors demonstrated that parathyroid autografts 
secret hormone and maintain normal serum calcium in the host (Wells et al., 1975; Hickey & 
Samaan, 1975). Oktay was the first to begin reimplanting of heterotopic tissue in the 
forearm, paving the way to human reimplantation history. In 2004 Oktay published a paper 
on the first embryo development after heterotopic transplantation of cryopreserved ovarian 
tissue (Oktay et el., 2004).  
Successful orthotopic transplantation of ewe cryopreserved ovarian tissue was first 
performed by Gosden in 1994 (Gosden et al., 1994). The orthotopic transplantation is the site 
most suitable compared to the heterotopic site, because it is the natural environment, with 
comfortable temperatures and pressures for proper follicular development.  
After several animal studies, ten years later, the first live human birth after frozen-thawed 
ovarian cortex orthotopic reimplantation was achieved by the Belgian group led by Donnez 
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(Donnez et al., 2004), followed recently by other live births (Donnez et al., 2011-a; Donnez et 
al., 2011-b; Meirow & Levron, 2005; Meirow et al., 2007; Demeestere et al., 2007; Demeestere 
et al., 2009; Anderson et al., 2008; Ernst  et al., 2010;  Silber et al., 2010; Piver et al., 2009; 
Sanchez-Serrano et al., 2010; Revel et al., 2011; Roux et al., 2010), as shown in table 1.  
The major disadvantage of transplanting ovarian cortical strips is that revascularization of 
the graft needs several days, according to the species. So, revascularization occurrs within 
48h after transplantation in rats and within 1 week of grafting in sheep. This leads to great 
loss of follicles from the grafts in transplantation due to ischemic injury, which can however 
be avoided by performing a whole ovarian transplantation thus providing immediate 
revascularization of the transplant (Onions et al., 2009; Bedaiwy & Falcone, 2004; Bedaiwy et 
al., 2006; Bromer & Patrizio, 2009). However, whole ovarian transplantations have a high 
rate of vascular complication, such as risk of thrombosis. Therefore, further work is needed 
before whole ovarian tissue transplantation can be considered a viable option for fertility 
preservation.  
Exogenous factors such as antioxidants, growth factors or hormones have been tested to 
improve follicular survival in ovarian grafts by reducing ischaemia-reperfusion injury 
(Nugent et al., 1998; Torrents et al., 2003;  Demeestere et al., 2009). 
Until now, slow programmed ovarian tissue freezing is the only procedure that has resulted 
live births following orthotopic transplantation of frozen/thawed human ovarian tissue 
slices, but it is unknown or difficult to quantify how many women have attempted ovarian 
tissue reimplant.  
The risk of ovarian tissue reimplantation includes transplantation of the primary tumour.  
However, most malignant diseases encountered during the reproductive years do not 
metastasize to the ovaries, except blood-borne malignancies such as leukemias, neuroblastoma 
and Burkitt’s lymphoma.  In the 1996 Shaw reported the transmission of lymphoma from a 
donor to a graft recipient (Shaw et al., 1996). Recently, Dolmans demonstrated, by quantitative 
RT-PCR, ovarian contamination by malignant cells by reimplant cryopreserved ovarian tissue 
in acute and chronic leukaemia patients (Dolmans et al., 2011).  
So, it is highly recommended to use the best assessment to detect micro-metastases on a 
small portion of the harvested tissue before cryopreservation, it is also useful to freeze a less 
valuable part of the cortex, such as ovarian medulla.   
As suggested by Von Wolff, sophisticated techniques are required to exclude first 
macroscopic ovarian pathology, such as ovarian metastasis, using imaging (sonography, CT 
scan, etc.). Then immunohistochemistry and polymerase chain reaction (PCR) to exclude 
single malignant cells, and identified minimal residual disease (MRD) by highly sensitive 
RT-PCR. Another effective method  is xenotransplant  small sample  of ovarian tissue in a 
immunodeficient animal host (Von Wolff et al., 2009). 
4.3 Xenotransplantation 
Xenotransplantation falls between reimplantation and in vitro culture, so the follicles within 
the tissue are growing in vivo in an animal host (T-and B-cell-deficient SCID mice). It has 
been applied to assess the risk of reimplanting malignant cells after human ovarian tissue 
reimplantation, and to observe follicle development.   
Last year Dath compared four grafting (intraperitoneal, ovarian bursa, sub-cutaneous, and 
intramuscular) sites for xenotransplantation of human ovarian tissue to nude mice, 
concluding that all four sites equally supported early follicular growth and preserved some 
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quiescent follicles (Dath et al., 2010). However, Sonmezer reported an asynchrony between 
oocytes and granulosa cell development (Sonmezer  & Oktay, 2010). 
 
FIRST 
AUTHOR 
YEAR 
WHERE DIAGNOSIS AGE 
at 
cryo 
FRESH or CRYO-
PRESERVED 
SLICES or 
WHOLE 
REIMPLANTATION 
SIDE 
OUTCOME 
Donnez,   
2004 
Belgium Stage IV 
Hodgkin’s 
lymphoma 
25 Frozen/thawed Slices Orthotopic: ovarian 
fossa peritoneum 
Spontaneous 
pregnancy: 
live birth 
Donnez, 
2011-a 
Belgium Neuroectoder
mic tumour 
17 Frozen/thawed Slices Orthotopic: ovary Spontaneous 
pregnancy: 
live birth 
Meirow, 
2005, 2007 
Israel Non 
Hodgkin’s 
lymphoma 
28 Frozen/thawed Slices Orthotopic: ovary Mild ovarian 
stimulation - 
IVF: live birth 
Demeester
e, 2007, 
2010 
Belgium Stage IV 
Hodgkin’s 
lymphoma 
24 Frozen/thawed Slices Orthotopic (+ 
heterotopic) 
Spontaneous 
pregnancy:  
live birth in 
2007 
live birth in 
2009 
Andersen, 
2008 
Denmark Hodgkin’s 
lymphoma 
27 Frozen/thawed Slices Orthotopic: ovary Ovarian 
stimulation -  
IVF: live birth 
Andersen, 
2008; 
Ernst, 
2010 
Denmark Ewing  
sarcoma 
27 Frozen/thawed Slices Orthotopic: ovary Mild ovarian 
stimulation - 
IVF: 1 live 
birth. 
Spontaneous 
pregnancy: 
1 live birth 
A- Silber, 
2010 
B-
(Donnez, 
2011 b) 
USA Stage IIIb 
Hodgkin’s 
lymphoma 
20 Frozen/thawed Slices Orthotopic A- Ongoing 
pregnancies 
 
B -live birth 
Silber, 
2010 
USA  24 Frozen/thawed Slices Orthotopic 1 live birth 
+ 
1 live birth 
Piver, 
2009 
France Microscopic 
polyangiitis 
27 Frozen/thawed Slices Orthotopic IVF: live birth 
Sanchez-
Serrano, 
2010 
Spain Breast cancer 36 Frozen/thawed Slices Orthotopic Ovarian 
stimulation, 
IVF: 2 live 
births (twins) 
Revel, 
2011 
Israel Thalassemia 
major 
19 Frozen/thawed Slices Orthotopic IVF: live birth 
Roux,        
2010 
France Homozygous 
sicule cell 
anemia 
20 Frozen/thawed Slices Orthotopic: ovary and 
few strips deposited in 
the peritoneal window 
Spontaneous 
pregnancy: 
live birth 
Table 1. Live births after frozen/thawed orthotopic transplantation of human ovarian tissue.  
In conclusion, xenotransplantation should be carefully considered in its human clinical 
application because of the risk of cross-species retroviral infection.  
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5. Conclusion 
As reported by Maltaris it is important to assess the ‘ovarian reserve’ that is the available 
pool of primordial follicles in the ovary and is a major determinant of female fertility 
potential. This information is important for a correct strategy of fertility preservation before 
cancer treatment. In general, ovarian reserve tests are either biochemical or biophysical 
(Maltaris et al., 2006), but new methods are required. 
In conclusion, a common goal of life-saving methods must be to protect the fertility of 
young women to this aim it is important to form a closely collaborative team comprising 
gynaecologists, surgeons, oncologists, haematologists, biologists and psychologists. 
Specifically, it is important that the oncologist gives an assessment of the degree of ovarian 
damage in order to decide how much ovarian tissue to retrieve and store.  
It is known that for each malignant disease only few protocols are commonly used, so it is 
possible to analyse the risk of ovarian failure. Meirow reported that the ovarian failure rate 
was 50% for breast cancer, 44% for non-Hodgkin’s lymphoma, and 32% for Hodgkin’s 
disease (Meirow & Nugent, 2001). 
Before proceeding to cryopreserve ovarian tissue, it is important to identify a series of tests 
for morphological analyses (such as staining with hematoxylin and eosin for observation by 
an optical microscope, or a more thorough evaluation of cell components by electron 
microscopy), for functional analyses (such as immunohistochemistry), or for viability 
analyses (such as trypan blue); in order to assess the degree of overall tissue preservation 
with the procedure adopted in the laboratory.  
In addition, it is also important to put an age limit to the preservation of ovarian tissue. The 
patient can use it only after cancer remission, therefore not before few years, so the  
cryopreservation of ovarian tissue of a patient older than 38 years old may be a useless 
procedure but could give psychological support to women. In any case, patients should be 
properly informed about the real possibility of recovering fertility and be able to get 
pregnant.  
In conclusion, we agree with Donnez that ovarian tissue cryopreservation should be offered 
before anticancer treatments in all cases where there is a high risk of  premature ovarian 
failure and where emergency in vitro fertilization is not possible (Donnez et al., 2011-c). 
If the dogma of reproductive biology is that of a finite number of follicles in the ovary 
which, moreover, undergo atresia during reproductive life, all procedures to preserve 
fertility should be carried out before acting on the ovary with drugs, therapies, surgery or 
potentially toxic treatments. Therefore, live births after cryoprserved ovarian tissue 
trasnplantation opened up new chapter in the field of infertility preservation.  
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